Work

Letter to the editor from Pantet al

Year: 2021

Type: editorial

Abstract: Dear Editor: In the previously published work ‘Phase 2 study of pembrolizumab in patients with advanced rare cancers’, we published in this journal by Naing et al ,[1][1] the checkpoint inhibitor pembrolizumab was evaluated in advanced rare cancers. Herein, we present the extraordinary longer-

Source: Journal for ImmunoTherapy of Cancer

DOI: 10.1136/jitc-2021-003991

Authors: Shubham Pant, Justin T Moyers, Aung Naing

Institutions: The University of Texas MD Anderson Cancer Center, University of California, Irvine

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490